Dupuytren disease

Disease Modifying AntiDupuytren Drugs
Sep 7, 2022

The path to a Dupuytren cure is connected to the story of drugs for rheumatoid arthritis. The evolution of rheumatoid drug treatment dates back centuries, based on guesswork and trial and error. During this time, hundreds of rheumatoid “cures” were recommended – herbs, diets, bedrest, baths, special clothing, radioactive exposure, special jewelry, injections of arsenic […]

Read more ›
Happy Holidays from DRG
On: Dec 22, 2021
By: Charles Eaton

When we all lend a hand helping the community we improve everyone’s quality of life. Best wishes in this holiday season from the Dupuytren Research Group

Read more ›
Podcast: Nine Dupuytren Questions
On: Oct 25, 2019
By: Charles Eaton

Here’s a fresh podcast reviewing the state of Dupuytren disease in 2019. In this podcast, Dr. Eaton of the Dupuytren Research Group reviews these 9 topics: What is Dupuytren Disease? Why do people develop it? What happens over time? How is it measured? How to prevent progression? How is it treated? Why is recurrence such a problem? Why is it so different […]

Read more ›
Dupuytren Rare Champion of Hope Award
On: Sep 24, 2019
By: Charles Eaton

I just returned from the 2019 Global Genes Rare Advocacy Summit with the Rare Champion of Hope award in the category of science. It was one of the most exciting and inspirational meetings I’ve attended, filled with successful disease advocates, brilliant researchers, and leaders in genomic and advocacy technologies. What I learned there will change […]

Read more ›
DRG goes to Washington
On: Jul 21, 2019
By: Charles Eaton

On July 10th and 11th, the Dupuytren Research Group went to Washington DC. We visited offices of Congressional representatives and other organizations to raise awareness about the impact of Dupuytren disease and the need for federal funding of Dupuytren research. Right now, there are no federal funds directed specifically for Dupuytren research – not at […]

Read more ›
Grants.gov: $0 for Dupuytren Research
On: Feb 8, 2019
By: Charles Eaton

Currently, there are no government grants for Dupuytren research. See for yourself: We’re working to change this. You should, too. If you have an idea you want to work on to help jumpstart government funding for Dupuytren Research, let us know! Charles Eaton MD

Read more ›
Dupuytren: restoring balance vs. winning the war
On: Jan 10, 2019
By: Charles Eaton

There were a number of responses to the last blog post. Annie Stratton wrote something so insightful I’ve included it with permission at the end of this post. The last post used the analogy of war, the war on Dupuytren. That seemed reasonable for several reasons – the importance of strategy and tactics, the concept of […]

Read more ›
PrecisionFDA Dupuytren Blog
On: Dec 6, 2018
By: Charles Eaton

PrecisionFDA Dupuytren Blog PrecisionFDA https://precision.fda.gov/ is a US Government initiative designed to support cutting-edge genomic research and help researchers collaborate across the globe. As a member of PrecisionFDA, Dupuytren Research Group will use PrecisionFDA cloud hosting to allow authorized researchers around the world to collaborate and analyze data from the International Dupuytren Data Bank (IDDB). Data […]

Read more ›
Happy Birthday, Dupuytren!
On: Oct 5, 2018
By: Charles Eaton

Today Would Have Been Dupuytren’s Birthday Guillaume Dupuytren (10/5/1777 – 2/8/1835) was born on this day in Pierre-Buffières, France. He excelled in anatomic studies and was appointed assistant surgeon at the Hôtel-Dieu in Paris at the age of 26. He rose to the position of head surgeon at the Hôtel-Dieu and remained so until his […]

Read more ›
Women with Dupuytren disease
On: Oct 4, 2018
By: Charles Eaton

Women with Dupuytren Disease A traditional Dupuytren narrative is that Dupuytren is primarily a painless nuisance problem of bent fingers in old men. This perception does a disservice to many. Not only is Dupuytren common in women, it may also present a unique burden to women. Updating the traditional narrative is central to raising awareness […]

Read more ›